Literature DB >> 1615177

Inhaled steroids in patients with bronchiectasis.

J S Elborn1, B Johnston, F Allen, J Clarke, J McGarry, G Varghese.   

Abstract

The effect of inhaled beclomethasone diproprionate (1500 micrograms day-1) on symptoms, pulmonary function and sputum production was examined in a double-blind, placebo-controlled, cross-over study in 20 patients with bronchiectasis. An 18% reduction in daily sputum production (P less than 0.003) was observed on treatment with inhaled steroid compared to placebo. A small, significant, improvement in morning peak expiratory flow rate (P less than 0.03) and forced expiratory volume in 1 s (P less than 0.03) was seen but the absolute changes are unlikely to be of clinical importance. Symptom scores for cough improved significantly (P less than 0.02). Inhaled steroids may have a role in the management of bronchiectasis by reducing cough and sputum production.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1615177     DOI: 10.1016/s0954-6111(06)80227-1

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  13 in total

1.  Inhaled fluticasone in bronchiectasis: a 12 month study.

Authors:  K W Tsang; K C Tan; P L Ho; G C Ooi; J C Ho; J Mak; G L Tipoe; C Ko; C Yan; W K Lam; M Chan-Yeung
Journal:  Thorax       Date:  2005-03       Impact factor: 9.139

Review 2.  Pharmacological treatment options for bronchiectasis: focus on antimicrobial and anti-inflammatory agents.

Authors:  Jonathan Ilowite; Peter Spiegler; Heather Kessler
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 3.  Diagnosis and management of bronchiectasis.

Authors:  Maeve P Smith
Journal:  CMAJ       Date:  2017-06-19       Impact factor: 8.262

4.  Increased levels of exhaled carbon monoxide in bronchiectasis: a new marker of oxidative stress.

Authors:  I Horvath; S Loukides; T Wodehouse; S A Kharitonov; P J Cole; P J Barnes
Journal:  Thorax       Date:  1998-10       Impact factor: 9.139

5.  Budesonide efficacy and safety in patients with bronchiectasis not due to cystic fibrosis.

Authors:  Rosana Hernando; María Estrella Drobnic; María Jesús Cruz; Adelaida Ferrer; Pilar Suñé; J Bruno Montoro; Ramon Orriols
Journal:  Int J Clin Pharm       Date:  2012-06-09

6.  Increases in CD4+ T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis.

Authors:  M Gaga; A M Bentley; M Humbert; J Barkans; F O'Brien; C G Wathen; A B Kay; S R Durham
Journal:  Thorax       Date:  1998-08       Impact factor: 9.139

Review 7.  Is there a role for inhaled corticosteroids and macrolide therapy in bronchiectasis?

Authors:  Paul King
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 8.  Bronchiectasis in older patients with chronic obstructive pulmonary disease : prevalence, diagnosis and therapeutic management.

Authors:  Deborah Whitters; Robert A Stockley
Journal:  Drugs Aging       Date:  2013-04       Impact factor: 3.923

Review 9.  Severe bronchiectasis.

Authors:  Brian M Morrissey; Samuel J Evans
Journal:  Clin Rev Allergy Immunol       Date:  2003-12       Impact factor: 8.667

Review 10.  Inhaled corticosteroids for bronchiectasis.

Authors:  Nitin Kapur; Helen L Petsky; Scott Bell; John Kolbe; Anne B Chang
Journal:  Cochrane Database Syst Rev       Date:  2018-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.